The Nu Game Changer in Cancer Treatment

Our cancer targeting
tech improves patient
outcomes, shortens
treatment, and reduces
healthcare costs.

Our NV-VPAC1 delivery system makes diagnosing, targeting and killing cancer more effective than ever before.

With the latest technology our In Vivo and In Vitro solutions are taking cancer treatment to the next level.

Led by a multi-disciplinary team of industry experts with decades of combined experience in healthcare and medical imaging technologies, NuView Life Sciences is poised to change how we look for and respond to cancer.

In Vivo Diagnostics

a Positron Emission Tomography (PET) imaging agent for the in vivo diagnosis of breast and prostate cancer

In Vitro Diagnostics

an in vitro diagnostic kit that may be used for detecting shed prostate and bladder cancer cells in voided urine

Theranostics Applications

NuView is preparing to expand its portfolio for Theranostics applications using the NV-VPAC1TM peptide analog…

From the Press


NuView Life Sciences Provides Corporate Update on NV-VPAC1 Theranostic for Breast Cancer

Developing a Novel Approach for the Future of Breast Cancer Diagnosis and Treatment PARK CITY, UT / ACCESSWIRE / October 5, 2022 / NuView Life…

Targeting VPAC1 Receptors for Imaging Glioblastoma

Sushil K Tripathi  1 , Rhonda Kean  2 , Emily Bongiorno  2 , Douglas C Hooper  2 , Yuan-Yuan Jin  3 , Eric Wickstrom  4   5 , Peter A McCue …
Press Releases

NuView Life Sciences Creates Subsidiary for Latin American Market

Introducing a New Approach to Diagnose and Treat Cancer PARK CITY, UT / ACCESSWIRE / November 17, 2021/  – NuView Life Sciences, Inc (“NuView”, the…

Would you like to read more?

Get Answers From the National Cancer Institute

Information specialists at NCI’s Cancer Information Service (CIS), NCI’s contact center, are available to help answer your cancer-related questions. The service is available in English and Spanish.

We are proud to support the American Red Cross